Kalender
| Est. tid* | ||
| 2026-02-12 | 07:30 | Bokslutskommuniké 2025 |
| 2025-11-25 | N/A | Extra Bolagsstämma 2025 |
| 2025-11-06 | 07:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-20 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-08 | - | Kvartalsrapport 2025-Q1 |
| 2025-04-29 | - | Årsstämma |
| 2025-04-24 | - | X-dag ordinarie utdelning ZLNA 0.00 NOK |
| 2025-04-01 | - | Split ZLNA 10:1 |
| 2025-01-31 | - | Bokslutskommuniké 2024 |
| 2024-11-06 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-07 | - | Kvartalsrapport 2024-Q1 |
| 2024-04-25 | - | X-dag ordinarie utdelning ZLNA 0.00 NOK |
| 2024-04-24 | - | Årsstämma |
| 2024-02-14 | - | Bokslutskommuniké 2023 |
| 2023-11-08 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-22 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-10 | - | Kvartalsrapport 2023-Q1 |
| 2023-04-21 | - | X-dag ordinarie utdelning ZLNA 0.00 NOK |
| 2023-04-20 | - | Årsstämma |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-11-10 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-19 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-12 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-21 | - | X-dag ordinarie utdelning ZLNA 0.00 NOK |
| 2022-04-20 | - | Årsstämma |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-11-11 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-20 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-11 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-22 | - | X-dag ordinarie utdelning ZLNA 0.00 NOK |
| 2021-04-21 | - | Årsstämma |
| 2021-02-17 | - | Bokslutskommuniké 2020 |
| 2020-11-12 | - | Kvartalsrapport 2020-Q3 |
| 2020-11-11 | - | Extra Bolagsstämma 2020 |
| 2020-08-21 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-14 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-16 | - | X-dag ordinarie utdelning ZLNA 0.00 NOK |
| 2020-04-15 | - | Årsstämma |
| 2020-02-14 | - | Bokslutskommuniké 2019 |
| 2019-11-14 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-21 | - | Kvartalsrapport 2019-Q2 |
Beskrivning
| Land | Norge |
|---|---|
| Lista | Oslo Bors |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a private placement (the "Private Placement"), divided on a first tranche of 3,729,774 new shares ("Tranche 1") and a second tranche of 1,770,226 new shares, and the allocation of 315,639 new shares in a retail offering via the PrimaryBid Platform (the "Retail Offering").
Radforsk Investeringsstiftelse ("Radforsk") holds 2,469,693 shares in the Company, representing 12.07% of the total number of shares and votes in the Company. Pursuant to a share lending agreement entered into in connection with the Private Placement and the Retail Offering, Radforsk has lent 742,289 existing shares to the manager for the Private Placement and Retail Offering, in order to facilitate delivery versus payment settlement of shares in Tranche 1 of the Private Placement and in the Retail Offering. Consequently, the shareholding of Radforsk will, upon the lending of such shares, temporarily cross below the 10% threshold pursuant to section 4-2 of the Norwegian Securities Trading Act, and its shareholding will at such time be 1,727,404 shares, equal to 8.45% of the total number of shares and votes in the Company.
Following issuance of the in total 4,045,413 new shares to be issued in Tranche 1 of the Private Placement and the Retail Offering, the shares lent out will be redelivered to Radforsk, and Radforsk will at such time again hold 2,469,693 new shares in the Company, which will at such time correspond to 10.08% of the total number of shares and votes in the Company.
This disclosure is made pursuant to Section 4-2 of the Norwegian Securities Trading Act.